KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress

A phase III study of prifetrastat will provide initial data on the clinical significance of KAT6 inhibitors. The application of Prifetrastat and other KAT6 inhibitors to wider breast cancer subpopulations and other solid tumors is anticipated. Additionally, mitigation strategies for dysgeusia and clinically available response-predictive biomarkers should be developed. KAT6 inhibitors with different target spectra, including KAT6A-selective and KAT6/7 inhibitors, may exhibit differential efficacy and safety profiles, offering deeper insights into KAT6-targeted therapy.